Kazia Therapeutics Announces Sovargen Co. Doses First Patient in Phase 1b/2a Trial of Paxalisib for Rare Seizure DisordersPRNewsWire · Sep 22, 2026
Kazia Therapeutics Announces First Patient Dosed in PNOC035 Clinical Study Evaluating Paxalisib for Recurrent Pediatric AT/RT Brain CancerPRNewsWire · Sep 9, 2026
Kazia Therapeutics Limited (KZIA) Discusses Clinical and Corporate Updates With Focus on Paxalisib Programs in Breast and Colorectal Cancer TranscriptSeeking Alpha · Sep 4, 2026
Kazia Therapeutics Reports Preclinical Data Showing Paxalisib Reprograms Immunotherapy-Resistant MSS/pMMR Colorectal Cancer and Enhances Response to ImmunotherapyPRNewsWire · Sep 1, 2026
Kazia Therapeutics Expands Paxalisib Clinical Trial into HR+/HER2- Breast Cancer, Supported by Preclinical Data Showing Strong Clinical Activity and Safety in HR+ Breast CancerPRNewsWire · Sep 1, 2026
Kazia Therapeutics Limited Announces Oversubscribed Closing of Up to $120 Million Public OfferingPRNewsWire · Aug 31, 2026Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel. The company's lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase II/III clinical trial for the treatment of glioblastoma; in Phase II trial to treat isocitrate dehydrogenase-mutant glioma, primary central nervous system (CNS) lymphoma, diffuse intrinsic pontine glioma, and brain metastases; and in pre-clinical studies to treat triple-negative breast cancer, as well as for the treatment of atypical rhabdoid/teratoid tumors. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3 that is in Phase I clinical trial to treat advanced solid tumors and ovarian cancer.
| Date | Est. | Actual | |
|---|---|---|---|
| Sep 4, 2026 | -$0.61 | -$0.46 | Beat |
| Mar 16, 2026 | -$0.01 | -$0.58 | Miss |
| Nov 7, 2025 | -$0.01 | -$0.43 | Miss |
| Jun 10, 2025 | -$10.76 | -$3.81 | Beat |
| Feb 20, 2025 | -$15.00 | -$20.80 | Miss |
| Sep 16, 2024 | -$3.00 | -$0.30 | Beat |